Rocket Pharmaceuticals, Inc. Common Stock RCKT
i
Market datapartial · fetched 2026-11-12T02:41:16.577Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-12T00:05:08.821617742Z
FundamentalsAlpha Vantage · unavailable
Rocket Pharmaceuticals, Inc. Common Stock options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | 4.34 | 238.3% | 75.6% | |||
| 25Δ | 4.09 | 231.1% | 66.9% | |||
| 30Δ | 3.84 | 223.9% | 58.2% | |||
| 35Δ | 3.60 | 216.8% | 49.5% | |||
| 40Δ | 3.35 | 209.6% | 40.8% | |||
| 45Δ | 3.10 | 202.4% | 32.1% | 2.65 | 196.1% | 11.5% |
| 50Δ | 2.86 | 195.2% | 23.4% | 2.99 | 223.2% | 10.5% |
| 55Δ | 2.61 | 188.0% | 14.7% | 3.32 | 250.3% | 9.6% |
| 60Δ | 3.66 | 277.4% | 8.7% | |||
| 65Δ | 3.99 | 304.5% | 7.7% | |||
| 70Δ | 4.33 | 331.6% | 6.8% | |||
| 75Δ | 4.66 | 358.7% | 5.9% | |||
| 80Δ | 5.00 | 385.8% | 5.0% | |||
20Δ
- Pseudo strike
- 4.34
- IV
- 238.3%
- B/E move
- 75.6%
- Pseudo strike
- IV
- B/E move
25Δ
- Pseudo strike
- 4.09
- IV
- 231.1%
- B/E move
- 66.9%
- Pseudo strike
- IV
- B/E move
30Δ
- Pseudo strike
- 3.84
- IV
- 223.9%
- B/E move
- 58.2%
- Pseudo strike
- IV
- B/E move
35Δ
- Pseudo strike
- 3.60
- IV
- 216.8%
- B/E move
- 49.5%
- Pseudo strike
- IV
- B/E move
40Δ
- Pseudo strike
- 3.35
- IV
- 209.6%
- B/E move
- 40.8%
- Pseudo strike
- IV
- B/E move
45Δ
- Pseudo strike
- 3.10
- IV
- 202.4%
- B/E move
- 32.1%
- Pseudo strike
- 2.65
- IV
- 196.1%
- B/E move
- 11.5%
50Δ
- Pseudo strike
- 2.86
- IV
- 195.2%
- B/E move
- 23.4%
- Pseudo strike
- 2.99
- IV
- 223.2%
- B/E move
- 10.5%
55Δ
- Pseudo strike
- 2.61
- IV
- 188.0%
- B/E move
- 14.7%
- Pseudo strike
- 3.32
- IV
- 250.3%
- B/E move
- 9.6%
60Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 3.66
- IV
- 277.4%
- B/E move
- 8.7%
65Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 3.99
- IV
- 304.5%
- B/E move
- 7.7%
70Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 4.33
- IV
- 331.6%
- B/E move
- 6.8%
75Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 4.66
- IV
- 358.7%
- B/E move
- 5.9%
80Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 5.00
- IV
- 385.8%
- B/E move
- 5.0%
Options history
Table
| Date | IV (%) |
|---|---|
| 157.38% | |
| 148.51% |
Biotechnology
RCUS
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and markets cancer therapies in the United States. The company is headquartered in Hayward,…
More →REGN
Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York. Originally focused on neurotrophic factors and their…
More →REPL
Replimune Group, Inc., a biotechnology company, develops oncolytic immunogenic therapies to treat cancer. The company is headquartered in Woburn, Massachusetts.
More →RGNX
REGENXBIO Inc., a clinical-stage biotechnology company, offers candidate gene therapy products to deliver genes to cells to address genetic defects or to enable cells in the body…
More →RIGL
Rigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat blood disorders, cancer, and rare immune diseases. The company is…
More →RLAY
Description unavailable
More →